What stage does Truffle Capital invest at?

Truffle Capital invests at the Seed, Series A, Series B, Series C, Growth stages.

What is Truffle Capital's typical check size?

Truffle Capital typically writes checks of $5M – $15M.

Where is Truffle Capital located?

Truffle Capital is headquartered in Paris, FR.

Does Truffle Capital lead rounds?

Yes, Truffle Capital leads investment rounds.

Truffle Capital

Venture capital

Paris · Seed–Growth · 5 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Truffle Capital positions itself as a European 'Business Builder' focused on two areas of expertise: Life Sciences (MedTech and Biotech) and Deeptech applied to finance (Fintech and Insurtech). It aims to create and grow companies into future leaders in BioMedTech and Finance/Insurance. Consistent with its model, the firm systematically acts as a founder in BioMedTech, serves as lead investor in financing rounds, and takes a proactive role in company governance.

Invests inAI & Machine Learning Biotech Crypto & Web3 Cybersecurity Deep Tech Fintech Healthtech InsurTech Medical DevicesEuropeParis

Source: firm website, verified Aug 3, 2026.

Stage

Seed–Growth

Check

$5M – $15M

Paris, FR

Leads rounds

Leads

Instruments

Equity

Founded

2001

AUM

$540M

Tracked investments

Team · 5 people

from the firm's website & public directories

Henri Moulard· Chairman & Co-Founder

Chairman & Co-Founder of Truffle Capital, formerly Chairman & CEO of Generali and Chairman of Banque Neuflize, ABN Amro France, and an Officer of the Legion d'Honneur.

Philippe Pouletty· CEO and Co-Founder

Medical doctor and serial entrepreneur, founder of Abivax and Carvolix, inventor of 39 patents, and a member of the Stanford Inventor Hall of Fame with a background in immunology at the Pasteur Institute.

p•••@truffle.comreveal

Bernard-Louis Roques· Co-Founder and CEO· Greater Paris Metropolitan Regionin

Co-founder and co-CEO of Truffle Capital, leading the firm alongside Philippe Pouletty.

b•••@truffle.comreveal

Julienne Nko'o· Senior Fund Controller

Nobel Negou· Senior Fund Controller

What they invest in

from 2 of 3 portfolio companies

Biotech ×2Healthtech ×1Medical Devices ×1

HQs:United States×1

Investments · 3 tracked

founders shown can be your intro path

VaxinMar 2015SEC filingmedium confidence

BiotechGaithersburg, US

Philippe Pouletty(Director)Scot Roberts(Executive Officer)Florent Gros(Director)Philip Hodges(Director)Klaus Schafer(Director)William Enright(Executive Officer, Director)

Board seatPhilippe Pouletty· per SEC Form D · $16M raise · filed Mar 2015

Abivaxabivax.comin 𝕏

Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.

BiotechHealthtechMedical Devices

Carvolix

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Frequently asked questions

What stage does Truffle Capital invest at?: Truffle Capital invests at the Seed, Series A, Series B, Series C, Growth stages.
What is Truffle Capital's typical check size?: Truffle Capital typically writes checks of $5M – $15M.
What sectors does Truffle Capital focus on?: Truffle Capital focuses on AI & Machine Learning, Biotech, Crypto & Web3, Cybersecurity, Deep Tech, Fintech, Healthtech, InsurTech, Medical Devices.
Where is Truffle Capital located?: Truffle Capital is headquartered in Paris, FR.
Does Truffle Capital lead rounds?: Yes, Truffle Capital leads investment rounds.

Media · Podcasts & interviews

featuring the team

Bernard-Louis Roques Directeur Général Truffle Capital : "C'est une année charnière pour les édit...

LABOURSEETLAVIE · Bernard-Louis Roques

Philippe Pouletty (Truffle Capital&Abivax) : Abivax annonce son introduction au Nasdaq

BFM Business · Philippe Pouletty

Philippe Pouletty (Truffle Capital) : Affluent Medical développe des valves cardiaques artificielles

BFM Business · Philippe Pouletty

Bernard-Louis Roques (Truffle Capital) : Les éditeurs de logiciel préoccupés par leur rentabilité

BFM Business · Bernard-Louis Roques

Palmarès Fintech 100 | Bernard-Louis Roques, Directeur Général, Truffle Capital

Finance Innovation · Bernard-Louis Roques

COVID-19H : Philippe Pouletty, co-fondateur et directeur général de Truffle Capital

Biotech Finances · Philippe Pouletty

Images

Similar investors

Elaia

Elaia is a venture capital firm that partners with entrepreneurs from company inception through to market leadership, supporting them across their growth journey.

$108K – $1.6M

OMERS Ventures

OMERS Ventures is the venture capital arm of the OMERS pension plan, investing in early-stage technology founders building solutions across North America and Europe.

$3.6M – $18.3M

MDI Ventures

MDI Ventures is the corporate venture capital arm of Indonesia's Telkom Group, investing in technology startups and emphasizing measurable social and environmental impact alongside financial returns.

$500K – $75M

Khosla Ventures

Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.

$5K – $50M

INP Capital

INP Capital is a global investment firm that invests across the full company life cycle, from early stage to pre-IPO, seeking to identify and back emerging technology companies as they scale toward unicorn status.